Search

Displaying results 2241 - 2250 of 10000 in total
  1. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [L42425] Pegloticase has a longer terminal elimination half-life thanks to the addition of a polyethylene glycol (PEG) group. … [A249980] The PEG group also gives pegloticase a lower potential to induce an immune response.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Me-4(18F)DG

    go.drugbank.com/drugs/DB19207
    Investigational

    Me-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).

  3. Drug

    Ecamsule

    go.drugbank.com/drugs/DB09534
    Approved

    Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … The company got approval for those products through a new drug application process.

    Mixtures: La Roche Posay Laboratoire Dermatologique Anthelios SX Daily Moisturizing Sunscreen Broad Spectrum SPF 15, Gelee Fraiche Hydratante SPF 15Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.[A275063, A275068]

    Mixtures: ALJIL 150 MG/300 MG/50 MG TABLET, 20 ADET, MINOSET PLUS 250 MG/150 MG/50 MG TABLET, 20 ADET
  5. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.

  6. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that

  8. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].

  9. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone … Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  10. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.

    International brands: Delorazepam EGProducts: DELORAZEPAM EG